Merck & Co Inc v Generics (UK) Ltd [2003] EWHC 2842 (Pat) (27 November 2003)
The patent claims are clear and specific, limiting protection to the use of methanesulfonic acid and the detailed process steps as claimed. The notional skilled reader cannot be reasonably confident that the patentee intended to cover sulphonic acids other than MSA or processes with materially different parameters....
Source-derived case information.
- Citation
- [2003] EWHC 2842 (Pat)
- Parties
- Claimant: Merck & Co Inc; Defendant: Generics (UK) Limited
- Jurisdiction
- England and Wales
- Judgment Date
- 27 November 2003
- Procedural Posture
- Patent Infringement / Trial Judgment
- Outcome
- Claim dismissed; no infringement found.
- Legal Topics
- Patent Construction, Infringement, Protocol on Interpretation, Purposive Construction
Source-derived case record
Summary, issues, holding and outcome
More case intelligence is available
Unlock the full research layer for this judgment.
Parties
Merck & Co Inc
Claimant
Generics (UK) Limited
Defendant
Procedural Posture
Patent Infringement / Trial Judgment
Legal Issues
- 1 Does the CIPLA process infringe Patent EP (UK) No. 0,402,152?
- 2 What is the proper construction of the patent claims under UK and EPC law?
Ratio Decidendi
The patent claims are clear and specific, limiting protection to the use of methanesulfonic acid and the detailed process steps as claimed. The notional skilled reader cannot be reasonably confident that the patentee intended to cover sulphonic acids other than MSA or processes with materially different parameters. The CIPLA process does not infringe the patent as it falls outside the scope of the claims.
Court Disposition
Claim dismissed; no infringement found.
Orders
- No injunction granted.
- No declaration of infringement.
Full Case Text
Judgment text and source record
Sign in to read
Sign in to read the full judgment text
Sign in to read the full judgment text. Downloads and additional research tools may depend on your plan.
Sign in to read the full judgment